To include your compound in the COVID-19 Resource Center, submit it here.

Global Blood discontinues GBT440 for IPF

Global Blood Therapeutics Inc. (NASDAQ:GBT) said it will discontinue development of GBT440 to treat idiopathic pulmonary fibrosis and

Read the full 189 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE